Waters Corp /De/ (NYSE: WAT)

Sector: Healthcare Industry: Diagnostics & Research CIK: 0001000697
Market Cap 23.59 Bn
P/B 10.12
P/E 36.37
P/S 7.60
ROIC (Qtr) 19.20
Div Yield % 0.00
Rev 1y % (Qtr) 8.05
Total Debt (Qtr) 1.49 Bn
Debt/Equity (Qtr) 0.64

About

Waters Corporation, a prominent entity in the analytical instruments and software industry, has been at the forefront of innovations in chromatography, mass spectrometry, and thermal analysis for over 65 years. With a global workforce of approximately 7,900 employees, the company directly operates in over 35 countries and caters to more than 100 countries worldwide. Waters' primary business activities encompass the design, manufacturing, sale, and service of high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography...

Read more

Price action

Investment thesis

Bull case

  • Strong operating cash flow of 728.14M provides robust 0.49x coverage of total debt 1.49B, indicating excellent debt servicing capability and financial flexibility.
  • Operating cash flow of 728.14M provides strong 14.18x coverage of stock compensation 51.34M, indicating sustainable incentive practices.
  • Robust free cash flow of 602.26M exceeds capital expenditure of 125.88M by 4.78x, indicating strong organic growth funding capability.
  • Tangible assets of 2.95B provide exceptional 9.80x coverage of deferred revenue 301.34M, showing strong service capability backing.
  • Retained earnings of 10.21B provide full 10.23x coverage of long-term debt 997.68M, indicating strong internal capital position.

Bear case

  • Operating cash flow of 728.14M barely covers its investment activities of (162.23M), with a coverage ratio of -4.49, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of (162.23M) provide weak support for R&D spending of 195.73M, which is -0.83x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Cash reserves of 459.12M provide limited coverage of acquisition spending of (33.56M), which is -13.68x, suggesting aggressive expansion might strain liquidity if market conditions deteriorate.
  • Free cash flow of 602.26M represents just -1.36x of debt issuance (442.99M), suggesting concerning reliance on leverage rather than internal cash generation for growth.
  • Retained earnings of 10.21B provide limited buffer against comprehensive income items of (111.17M), which is -91.81x, indicating elevated exposure to market risks.

Geographical Breakdown of Revenue (2024)

Product and Service Breakdown of Revenue (2024)

Peer comparison

Companies in the Diagnostics & Research
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 TMO Thermo Fisher Scientific Inc. 234.48 Bn 35.69 5.36 35.68 Bn
2 DHR Danaher Corp /De/ 171.11 Bn 48.85 7.05 16.86 Bn
3 IDXX Idexx Laboratories Inc /De 57.62 Bn 56.08 13.83 1.09 Bn
4 IQV Iqvia Holdings Inc. 42.37 Bn 33.03 2.66 15.19 Bn
5 A Agilent Technologies, Inc. 42.16 Bn 32.36 6.07 3.35 Bn
6 NTRA Natera, Inc. 31.64 Bn -102.32 14.95 0.18 Bn
7 MTD Mettler Toledo International Inc/ 30.89 Bn 36.96 7.84 2.21 Bn
8 WAT Waters Corp /De/ 23.59 Bn 36.37 7.60 1.49 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 5.09 2.82
EV to Cash from Ops. EV/CFO 34.01 19.55
EV to Debt EV to Debt 16.66 54.87
EV to EBIT EV/EBIT 29.42 18.82
EV to EBITDA EV/EBITDA 24.12 4.36
EV to Free Cash Flow [EV/FCF] EV/FCF 41.12 17.63
EV to Market Cap EV to Market Cap 1.05 1.58
EV to Revenue EV/Rev 7.97 5.06
Price to Book Value [P/B] P/B 10.12 1.35
Price to Earnings [P/E] P/E 36.37 18.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -2.00
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 2.86
Dividend per Basic Share Div per Share (Qtr) 0.00 0.19
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 1.94
Interest Coverage Int. cover (Qtr) 11.34 -128.90
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 4.61 -35.01
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 38.91 23.84
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.25
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 0.10 9.72
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 3.74 -444.66
EBIT Growth (1y) % EBIT 1y % (Qtr) 3.07 8.29
EBT Growth (1y) % EBT 1y % (Qtr) 7.30 -6.03
EPS Growth (1y) % EPS 1y % (Qtr) 3.81 15.59
FCF Growth (1y) % FCF 1y % (Qtr) -2.88 56.57
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 5.54 185.75
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.64 0.57
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.01
Cash Ratio Cash Ratio (Qtr) 0.37 1.23
Current Ratio Curr Ratio (Qtr) 1.53 2.70
Debt to Equity Ratio Debt/Equity (Qtr) 0.64 -0.84
Interest Cover Ratio Int Coverage (Qtr) 11.34 -128.90
Times Interest Earned Times Interest Earned (Qtr) 11.34 -128.90
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 33.60 -97.22
EBIT Margin % EBIT Margin % (Qtr) 27.11 -115.64
EBT Margin % EBT Margin % (Qtr) 24.72 -114.24
Gross Margin % Gross Margin % (Qtr) 59.00 44.76
Net Profit Margin % Net Margin % (Qtr) 20.90 -113.12